Safety and Efficacy of Technosphere® Insulin Inhalation Powder and Lantus® Compared to Humalog® and Lantus® Over 16-Weeks

Diabetes, Type 1 Clinical Trial

Official title:

A Phase3, Multi-Center, Open-Label, Randomized, Clinical Trial Evaluating the Efficacy and Safety of Technosphere® Insulin Inhalation Powder in Combination With Lantus® Versus Humalog® in Combination With Lantus® in Subjects With Type 1 Diabetes Mellitus Over a 16-Week Treatment Period

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00700622
• Other study ID #: MKC-TI-117
• Status: Terminated
• Phase: Phase 3
• First received: June 16, 2008
• Last updated: October 9, 2014
• Start date: May 2008
• Est. completion date: March 2010

Study information

• Verified date: October 2014
• Source: Mannkind Corporation
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The objective of this study is to demonstrate that TI® Inhalation Powder combined with Lantus® is as effective as Humalog® combined with Lantus® on HbA1c.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 130
• Est. completion date: March 2010
• Est. primary completion date: November 2009
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• Men or women = 18 and = 80 years old

• Clinical diagnosis of type 1 diabetes mellitus for more than 12 months

• Body mass index (BMI) = 30 kg/m2

• Stable antidiabetic regimen of sc insulin therapy at a total daily dose = 1.5 IU/kg/day

• HbA1c > 7.0% and = 9.0%

• C-peptide level = 0.30 pmol/mL

• Nonsmokers (includes cigarettes, cigars, pipes, and chewing tobacco) for at least the preceding 6 months

• Negative urine cotinine defined as = 100 ng/mL

• Pulmonary function tests (PFTs):

• Forced expiratory volume in 1 second (FEV1) = 70% Third National Health and Nutrition Examination Survey (NHANES III) predicted

• FEV1 as a percentage of FEV1/forced vital capacity (FVC) = 70% (NHANES III) predicted

• Total lung capacity (TLC) = 80% predicted (Intermountain Thoracic Society [ITS])

• Single breath carbon monoxide diffusing capacity of the lung, hemoglobin-corrected (DLco-Hb) (uncorrected) = 70% predicted

• For the subset of subjects having Doppler echocardiograms: right ventricular systolic pressure (RVSP) = 40 mm Hg at Visit 1

• Written informed consent

Exclusion Criteria:

• Treatment with any type of antidiabetic drugs, other than sc insulin, within the preceding 12 weeks

• Two or more severe hypoglycemic episodes within 6 months of screening or episode of severe hypoglycemia between Visit 1 and Visit 5

• Any hospitalization or emergency room visit due to poor diabetic control within 6 months of Visit 1, or hospitalization or emergency room visit due to poor diabetic control between Visit 1 and Visit 5

• Severe complications of diabetes, in the opinion of the PI, including symptomatic autonomic neuropathy; disabling peripheral neuropathy; active proliferative retinopathy; nephropathy with renal failure, renal transplant, or dialysis; history of foot ulcers; nontraumatic amputations due to gangrene; or vascular claudication

• Previous exposure to an inhaled insulin product within 3 months of Visit 1

• History of insulin pump use within 6 weeks of Visit 1

• Allergy or known hypersensitivity to insulin or to any of the drugs to be used in the trial, or a history of hypersensitivity to TI Inhalation Powder or to drugs with a similar chemical structure

• Significant improvement in pre- to postbronchodilator spirometry at Visit 1 (defined as an increase of 12% and 200 mL in either FEV1 or FVC)

• History of chronic obstructive pulmonary disease (COPD), clinically proven asthma, or any other clinically important pulmonary disease (eg, obstructive sleep apnea) confirmed by pulmonary function testing or radiologic findings

• Inability to perform spirometry maneuvers meeting recommended American Thoracic Society (ATS) standards of acceptability and repeatability criteria

• Active respiratory infection (subject could return after 30 days from resolution for rescreening); if respiratory infection manifested after Visit 1 but before Visit 1 PFTs, subject was to be scheduled for PFTs after 30 days from resolution of respiratory infection. An additional hemoglobin was to be required

• Major organ system diseases, including:

• Seizure disorder

• Significant cardiovascular dysfunction or history within 3 months of Visit 1, eg, congestive heart failure (New York Heart Association [NYHA] Class III or IV), or serious arrhythmia, myocardial infarction, cardiac surgery, recurrent syncope, transient ischemic attacks, or cerebrovascular accident

• Uncontrolled hypertension with a systolic blood pressure > 180 mm Hg or diastolic blood pressure > 110 mm Hg at Visit 1 despite pharmacologic treatment

• Nephrotic syndrome; renal dysfunction or disease; serum creatinine > 2.0 mg/dL (0.11 mmol/L) in men and > 1.8 mg/dL (0.1 mmol/L) in women; or blood urea nitrogen (BUN) > 50 mg/dL (2.8 mmol/L)

• Cancer (other than excised cutaneous basal cell carcinoma) within the past 5 years or any history of lung neoplasms

• History of active viral or cirrhotic hepatic disease or abnormal liver enzymes as evidenced by serum aspartate aminotransferase (AST) or alanine aminotransferase (ALT) = 3 times the upper limit of normal (ULN)

• Active infection (eg, human immunodeficiency virus [HIV], hepatitis) or history of severe infection within 30 days of Visit 1

• Anemia (hemoglobin = 10.5 g/dL for women or = 11.5 g/dL for men)

• Diagnosis of systemic autoimmune or collagen vascular disease requiring previous or current treatment with systemic corticosteroids, cytotoxic drugs, or penicillamine

• Any concurrent illness, other than diabetes mellitus, not controlled by a stable therapeutic regimen

• Current or previous chemotherapy or radiation therapy that might result in pulmonary toxicity

• Use of medications prescribed for weight loss (eg, sibutramine, orlistat) within 12 weeks of Visit 1

• Any history of or current use of amiodarone

• Clinically significant abnormalities on screening laboratory evaluation (unless discussed with and approved by the medical monitor)

• Women who were pregnant, lactating, or planning to become pregnant during the trial

• Women of childbearing potential (defined as premenopausal and not surgically sterilized or postmenopausal for fewer than 2 years) not practicing adequate birth control. Adequate birth control was defined as using oral, percutaneous, or transdermal contraceptives; condoms and diaphragms (double barrier) with a spermicide; or intrauterine devices. Postmenopausal for this trial included amenorrhea for 2 or more years or surgically sterile

• Current drug or alcohol abuse or a history of drug or alcohol abuse that, in the opinion of the PI, would make the subject an unsuitable candidate for participation in the trial

• Exposure to any investigational medications or devices within 30 days before trial entry, or participation in another clinical trial while participating in this trial

• Unable or unlikely to comprehend and follow the trial protocol (including SBGM and diabetes education)

• Unable or unlikely to comprehend how to use the MedTone Inhaler or inability to use the device

• Unable or unlikely to follow a meal plan that included at least 2 meals/day (with or without a third meal or additional snacks)

• Noncompliance with medication or procedures that, in the PI's opinion, might affect the trial data or subject safety and that precluded the subject from further participation in the trial

• Any other concurrent medical or major psychiatric condition that, in the opinion of the PI, made the subject unsuitable for the clinical trial or could limit the validity of the informed consent or impair the subject's ability to participate in the trial

• For the subset of subjects having Doppler echocardiograms:

• Subjects with left ventricular ejection fraction (LVEF) = 35% at Visit 1

• Subjects with known history of sickle cell disease

• Previous use of Redux® (dexfenfluramine) or Pondimin® (fenfluramine)

• History of valvular heart disease, including mild or greater aortic insufficiency or moderate or greater mitral insufficiency

• Significant cardiovascular dysfunction or history within 12 months of Visit 1 (eg, congestive heart failure [NYHA Class III or IV]) or serious arrhythmia, treatment with medications to control or treat arrhythmias, myocardial infarction, cardiac surgery, recurrent syncope, transient ischemic attacks, or cerebrovascular accident

• History of pulmonary embolism or deep venous thrombosis in the 12 months before Screening

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Diabetes, Type 1

Intervention

Drug:
• Technosphere Insulin
Technosphere Insulin Inhalation Powder 15U or 30U
• Insulin glargine
Lantus-injectible supplied as 3mL (300 units) pens
• Insulin lispro
Humalog autopen cartridges pre-filled with 3mL (300 units)

Locations

Country	Name	City	State
Brazil	Centro de Pesquisas em Diabetes Ltda	Porto Alegre	RS
Brazil	CPClin-Centro de Pesquisas Clinicas	Sao Paulo
United States	Mountain Diabetes & Endocrine Center	Asheville	North Carolina
United States	Atlanta Diabetes Associates	Atlanta	Georgia
United States	Barbara Davis Center for Diabetes Young Adult Clinic	Aurora	Colorado
United States	AM Diabetes and Endocrinology Center	Barrtlett	Tennessee
United States	Deaconess Billings Clinic Research Center	Billings	Montana
United States	Baylor Endocrine Center	Dallas	Texas
United States	Dallas Diabetes & Endocrine Center	Dallas	Texas
United States	University of Texas Southwestern Medical Center	Dallas	Texas
United States	Endocrine Research Physicians East PA	Greenville	North Carolina
United States	Diabetes/Lipid Management and Research Center	Huntington Beach	California
United States	The Whittier Institute for Diabetes Clinical Trials	La Jolla	California
United States	Your Diabetes Endocrine Nutrition Group, Inc.	Mentor	Ohio
United States	University of Miami Diabetes Research Institute	Miami	Florida
United States	University of Miami School of Medicine	Miami	Florida
United States	Tulane University Health Sciences Center	New Orleans	Louisiana
United States	OHSU Diabetes Center Research Oregon Health & Science University	Portland	Oregon
United States	Dorothy L & James E Frank Diabetes Research Institute	San Mateo	California
United States	Diabetes Care Center	Seattle	Washington
United States	Diabetes Research Center -Fletcher Allen Health Care	South Burlington	Vermont
United States	Washington University School of Medicine	St. Louis	Missouri

Sponsors (1)

Lead Sponsor	Collaborator
Mannkind Corporation

Countries where clinical trial is conducted

United States,  Brazil, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change From Baseline in HbA1c to Week 16	Change from Baseline in glycosylated hemoglobin at Week 16	Baseline to Week 16	No